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Background: Ischaemic preconditioning (IPC) of the right liver graft in the donor has not been studied
in adult-to-adult living related liver transplantation (LRLT).
Objective: To assess the IPC effect of the graft on ischaemia reperfusion injury in the recipient and
compare recipient and donor outcomes with and without preconditioned grafts.
Patients and methods: Alternate patients were transplanted with right lobe grafts that were (n = 22;
Group Precond) or were not (n = 22; Group Control) subjected to IPC in the living donor. Liver ischaemia–
reperfusion injury, liver/kidney function, morbidity/mortality rates and outcomes were compared. Uni-
variate and multivariate analyses were performed to identify factors predictive of the aspartate
aminotransferase (AST) peak and minimum prothrombin time.
Results: Both groups had similar length of hospital stay, morbidity/mortality, primary non-function and
acute rejection rates. Post-operative AST (P = 0.8) and alanine aminotransferase (ALT) peaks (P = 0.6)
were similar in both groups (307  189 and 437  302 vs. 290  146 and 496  343, respectively). In
univariate analysis, only pre-operative AST and warm ischemia time (WIT) were significantly associated
with post-operative AST peak (in recipients). In multivariate analysis, the graft/recipient weight ratio
(P = 0.003) and pre-operative bilirubin concentration (P = 0.004) were significantly predictive of minimum
prothrombin time post-transplantation.
Conclusions: Graft IPC in the living related donor is not associated with any benefit for the recipient or
the donor and its clinical value remains uncertain.
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Introduction
Living related right lobe liver transplantation (LRRLLT) was a
breakthrough in the field of adult liver transplantation1 (for a
review see2,3). This technique increased the availability of grafts at
a time when there was a critical shortage of cadaveric organs
resulting in a very high death rate among patients on waiting lists.4
It may also improve the prognosis of certain indications.5,6 Use of
the right liver lobe has several advantages over use of the left lobe
for adult-to-adult liver transplantation: better anatomic position
for the vascular reconstruction, lower risk of hepatic venous
outflow block and increased hepatic mass. To ensure donor safety,
an adequate liver mass must be left to avoid post-operative hepatic
dysfunction. Several strategies have been designed to optimize
the function of the liver graft in the recipient and the remaining
liver in the donor. These include stringent selection of the donor
(with liver biopsy in many centres),2,3,7 preparation of the recipi-
ent, avoidance of vascular clamping during procurement, the
choice of the preservation solution and the shortest ischaemia
time possible.
This paper was presented at the International Hepato-Pancreato-Biliary
Association Meeting, 18–22 April 2010, Buenos Aires, Argentina.
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Several recent animal studies have shown that ischaemic pre-
conditioning (IPC) (especially brief exposure to warm ischemia)
provides robust protection against ischemia–reperfusion
injury during subsequent long periods of ischaemia. This phe-
nomenon was first described for the heart.8 It has since been
described inmany experimental models (for review see9,10) and for
several tissues and organs, including the liver.11–17 It has
been shown to be protective in three clinical studies on liver
resection.18–20 It has also been shown that a short period of warm
ischaemia protects different organs including the heart, intes-
tine, lung and kidney21,22 against subsequent cold ischaemia–
reperfusion injury. Several studies in experimental models23–25 and
humans26,27 suggest that IPC is suitable for use during liver trans-
plantation. The aim of the present study was to evaluate
the effects of IPC of the right lobe liver graft in the living donor on
ischaemia–reperfusion injury in the recipient. We compared the
rates of ischaemia–reperfusion injury, early graft function, mor-
tality, morbidity and patient survival in the two groups of recipi-
ents. We also assessed the impact of graft IPC on donor outcome.
Patients and methods
Objectives of the study
The primary end point of the study was the graft tolerance to
ischaemia reperfusion as assessed by the post-operative peak AST
concentration in the recipient.18–20 Secondary end points included
the analysis of the potential clinical relevance of IPC on early
graft function, mortality, morbidity and patient survival. We also
assessed the impact of graft IPC on donor outcome.
Study population and experimental design
This single centre prospective study was conducted during a
4-year period and included 44 consecutive cases of adult-to-adult
LRRLLT.Alternate patients were assigned to the two study groups.
Twenty-two patients received a graft that had been preconditioned
in the donor (Group Precond): 10 min of right pedicle clamping
including clamping of all arteries feeding the right liver, the right
portal branch(es) and the main bile duct, followed by 10 min of
reperfusion. Twenty-two patients received a graft that had not
been preconditioned (Group Control). LRRLLT performed during
the study period for fulminant hepatic failure (four cases) was the
only exclusion criteria from the study. The protocol of precondi-
tioning was identical to the one used in the two clinical studies
reported so far.18–20 The sample size calculation was based on the
results of the 15 first cases of LRRLLT performed at our centre, by
the same surgeon (D.A.) and without any vascular clamping. In
these 15 cases the mean peak aspartate aminotransferase (AST)
concentration was 274  126 IU/L (standard error = 27.6 IU/L).
The sample size needed to detect a significant difference for the
peak AST concentration was calculated as 22 cases on each group,
using a two-sided test (a = 0.05,b = 0.1). The protocol of the study
was approved by the investigation and review board of our centre.
Informed consent was obtained from all donors and recipients.
Surgical procedures
Right liver graft harvesting
The same procurement technique was used throughout the
study. This technique has been reported in detail previously.7 No
vascular clamping (except during the preconditioning stage, when
applied) was performed during the harvesting procedure. The
middle hepatic vein and/or the inferior hepatic vein were included
in the graft as indicated.28,29 The graft was perfused ex situwith 1 L
of cold University of Wisconsin (UW) solution. All donor hepa-
tectomies were performed by the same surgeon (D.A.).
Transplantation technique
In brief, the native liver was totally removed with caval preserva-
tion.30 A temporary porta-caval shunt was performed.31 The right
lobe was then implanted. A microscope was used for arterial and
biliary anastomosis in all cases. All graft implantations were per-
formed by the same surgeon (D.C.). Cold ischaemia time (CIT)
was defined as the time between devascularization in the donor
and portal reperfusion in the recipient. Warm ischaemia time
(WIT) was defined as the time between portal unclamping and
arterial revascularization. A liver biopsy was taken before closing
the abdomen. This biopsy was available for 19/22 (86%) and 20/22
(91%) of Group Control and Group Precond recipients, respectively
(P > 0.9). None of the graft was steatotic, as macrovacuolar
steatosis >20% of hepatocytes was never observed. Ischaemia–
reperfusion injury was classified as moderate to severe (vs. absent)
when at least 10% of hepatocytes were necrotic, mainly in the
centre of the lobule or disseminated throughout.32
Post-operative management
Donors
In addition to the usual post-operative care received after right
hepatectomy, we measured the indocyanine green clearance
rate at 15 min (ICG RT15′) and used CT imaging to measure the
volume33–35 of the remaining left liver 8 and 30 days after donation.
Recipients
Transplanted patients received a standard immunosuppres-
sive regimen including FK-506 and methylprednisolone. Early
outcome was assessed by1 measuring ischaemia–reperfusion liver
injury, as estimated by the peak AST concentration2 liver function
tests, including determination of the minimum prothombin time
and the peak bilirubin concentration within 10 days of transplan-
tation3 measuring primary non-function, defined as immediate
absence of graft function leading to retransplantation or death4.
For the later group, the following technical complications were
recorded: hemoperitoneum needing reoperation, and arterial,
portal, outflow and biliary complications. Histologically proven
acute rejection was recorded, provided it occurred within 6 weeks
of transplantation and needed increased immunosuppression.36
Post-operative mortality was defined as death occurring during
the initial hospitalization period after transplantation or within
60 days of transplantation.
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Data analysis
All quantitative data are expressed as mean  standard devia-
tion. A P-value < 0.05 was considered statistically significant.
Factors potentially predictive of the peak AST concentration in
the recipient within 10 days of transplantation were assessed by
univariate and multivariate analysis. The donor data included:
age, pre-operative liver function tests, duration of operation,
intra-operative blood loss, volume of autotransfusion and graft
preconditioning; and the recipient data included: age, gender,
pre-operative liver function tests, graft to recipient body weight
ratio, cold ischaemia time, warm ischemia time and transfusion
volume.
The same assessment was performed for the minimum pro-
thrombin time. For continuous variables, differences between the
groups were evaluated using the Student’s t-test. For discrete vari-
ables, data were expressed as counts and percentages and were
analysed using Fisher’s exact test. Survival rates were calculated
using the Kaplan–Meier method, and groups were compared with
the log rank test. All statistical analyses were performed using SAS
software (SAS Institute, Inc., Cary, NC, USA).
Biologists, intensive care specialists and pathologists were
not informed whether the graft had been subjected to ischaemic
preconditioning in the donor.
Results
Pre- and per-operative data (Tables 1 and 2)
The two donor groups were similar (Table 1) in terms of age
(P = 0.4), gender ratio (P = 0.5), pre-operative liver function tests
including the ICG RT15′ (P  0.2 in all cases), intra-operative data
including duration of operation (P = 0.08) and volume of auto-
transfused blood (P = 0.9). The remaining left liver to body weight
ratio was similar in the two groups (P = 0.2).
The two recipient groups were similar (Table 2) in terms of age
(P = 0.8), gender ratio (P > 0.9), indication for transplantation
(P = 0.5), liver function tests before transplantation (P > 0.2 in all
cases) and intra-operative data including graft-to-body weight
ratio (P = 0.7), cold ischaemia time (P = 0.6), warm ischaemia
time (P = 0.6) and number of blood units transfused (P = 0.9).
Donor outcome (Table 1)
The peak AST concentration was similar in the two groups of
donors (189.0  70.5 vs. 231.5  130.5 IU/L – group without vs.
with graft preconditioning, respectively, P = 0.2). Liver function
tests were similar at all time points, including ICG RT 15′ at day 8
(P = 0.8) and day 30 (P = 0.9), and volume of remaining left liver
at day 8 (P = 0.7) and day 30 (P = 0.6).
At least one complication occurred in 11 (morbidity rate =
50%) and 15 (morbidity rate = 68%) donors in the control and
preconditioned group, respectively (P = 0.7). None of these com-
plications were life-threatening. The duration of hospitalization
was similar in the two groups (P = 0.6). All donors were alive and
well at 24  15 months after donation.
Tolerance to ischaemia–reperfusion in recipients
(Table 2, Fig. 1)
We found no significant difference in serum concentrations of
AST and ALT between the two groups at any time point. Patients
Table 1 Pre-, per- and post-operative characteristics of right lobe donors
Characteristics Donor of (R) liver without
preconditionning
n = 22 cases
Donor of (R) liver with
preconditionning
n = 22 cases
P-value
Male/female (ratio) 6/16 8/14 0.5
Age (years) 37.8  13.1 41.4  15.4 0.4
Left liver to body weight ratio (%) 0.76  0.15 0.83  0.18 0.2
Duration of operation (minutes) 319  107 274  38 0.08
Number of blood units autotransfused 0.5  0.8 0.5  0.9 0.9
Peak AST (IU/L) 189.0  70.5 231.5  130.5 0.2
Peak ALT (IU/L) 193.1  81.1 236.9  135.2 0.2
Minimum prothrombin time (% of normal) 38.7  7.9 36.0  7.5 0.3
Peak bilirubin (mmol/L) 51.1  22.3 68.8  39.5 0.08
Morbidity rate n cases (%) 11 (50%) 15 (68%) 0.7
Duration of hospital stay (days) 13.4  6.4 14.1  4.1 0.6
ICG RT 15`
Day 8 12.7  4.2 12.1  6.7 0.8
Day 30 11.3  4.0 11.7  6.5 0.9
Left liver to body weight ratio (%)
Day 8 1.34  0.29 1.34  0.31 >0.9
Day 30 1.67  0.25 1.50  0.31 0.1
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
HPB 441
HPB 2010, 12, 439–446 © 2010 International Hepato-Pancreato-Biliary Association
in Group Precond had a similar peak AST concentration (307  189
vs. 290 146 IU/L, P = 0.4) and a similar peak ALT concentration
(437 302 vs. 496 343 IU/L, P = 0.8) as patients in Group control
(Fig. 1).
Factors associated with the maximum AST concentration
within 10 days of transplantation
Factors potentially predictive of the maximumAST concentration
in the recipient were assessed using univariate and multivariate
Table 2 Pre-, per- and post-operative characteristics of recipients
Characteristics Recipient of (R) liver without
pre-conditionning
n = 22 cases
Recipient of (R) liver with
pre-conditionning
n = 22 cases
P-value
Male/female (ratio) 17/5 18/4 >0.9
Age (years) 46.5  13.6 47.6  11.5 0.8




Graft to body weight ratio (%) 1.14  0.39 1.18  0.31 0.7
Cold ischaemia time (minutes) 87  31 92  28 0.6
Warm ischaemia time (minutes) 68  27 63  27 0.6
Number of blood units transfused 4.5  4.6 3.7  3.5 0.9
Peak AST (IU/L) 290  146 307  189 0.4
Peak ALT (IU/L) 496  343 437  302 0.8
Minimum prothrombin time (% of normal) 36.4  13.3 37.7  8.5 0.7
Bilirubin day 7 (mmol/L) 107  97 132  104 0.4
Duration of stay (days)
Overall 41.3  21.3 35.7  8.7 0.3
In intensive care unit 10.4  5.4 12.0  6.6 0.4
Morbidity n (%) 7 (31.8) 8 (36.4) 0.9
In-hospital mortality n (%) 2 (9) 1 (4.5) 0.5
Actuarial survival rate at 1 year (%)
Patient 86.1 95.5 0.08
Graft 88.9 80.2 0.6
AST, aspartate aminotransferase; ALT, alanine aminotransferase.






With (n = 22)
Without












Peak AST Peak ALT
Figure 1 Ischaemia–reperfusion injury in the recipient after living related right lobe liver transplantation (LRRLLT)
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analysis. The donor data included: age, pre-operative liver func-
tion tests, duration of operation, intra-operative blood loss,
volume of autotransfusion and graft preconditioning; and the
recipient data included: age, gender, pre-operative liver function
tests, graft-to-recipient body weight ratio, CIT, WIT and transfu-
sion volume.
Univariate analysis showed that only the pre-operative AST
concentration in the recipient and the warm ischaemia time were
associated with peak post-operative AST concentration (P = 0.04
and P = 0.03, respectively). Using multiple variable analysis none
of the later factors remained independently significant.
Graft function and factors associated with the minimal
prothrombin time
We found no significant difference in prothrombin time and
bilirubin concentration between the two groups of recipients at
any time point (Table 2, Fig. 2). Univariate analysis showed that
the following factors were associated with the minimal prothrom-
bin time: presence of cirrhosis (P = 0.01), the combination of
female donor to male recipient (P = 0.04), graft to recipient body
weight ratio (P = 0.02), number of blood units transfused in the
recipient (P = 0.02), pre-operative bilirubin concentration in the
recipient (P = 0.002), and recipient preoperative prothrombin
time (P = 0.006). None of the other factors tested were significant,
including preconditioning of the graft, CIT, and WIT (data not
shown). In the multivariate analysis, graft-to-recipient body
weight ratio (P = 0.003) and recipient pre-operative bilirubin
concentration (P = 0.004) remained independently associated
with the minimal prothrombin time.
Analysis of post-reperfusion biopsies
Analysis of post-reperfusion biopsies revealed no steatosis in any
of the grafts. Liver biopsies revealed ischaemia–reperfusion injury
in 2/20 (10%) and 4/19 (21%) of Group Precond and Group control
patients, respectively (P = 0.4).
Recipient outcome (Table 2)
Two patients in Group control and one patient in Group Precond died
within 60 days of transplantation (P = 0.5). Primary non function
occurred in one case in Group control and none in Group Precond
(P = 0.9). Technical morbidity occurred in 7/22 (31.8%) and 8/22
(36.4%) patients in Group control and Group Precond, respectively
(P = 0.9). The incidences of biliary complications (6/22 in
Group control and 7/22 in Group precond, P = 0.9), arterial thrombosis
(3/22 and 0/22, P = 0.2) and hemoperitoneum requiring reopera-
tion (3/22, and 0/22, P = 0.2) were similar in the two groups. We
observed no cases of portal vein thrombosis or outflow occlusion.
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Figure 2 Post-living related right lobe liver transplantation (LRRLLT) liver function tests with versus without graft preconditioning. Compa-
rision of groups was never statistically significant at any time point. AST, aspartate aminotransferase; ALT, alanine aminotransferase;
PT, prothrombin time
HPB 443
HPB 2010, 12, 439–446 © 2010 International Hepato-Pancreato-Biliary Association
The incidence of acute rejection needing increased immunosup-
pression was the same in Group control and Group Precond (4/22, and
1/22, P = 0.3).
The durations of stay in intensive care and in hospital were
similar in the two groups (P = 0.4 and P = 0.3, respectively).
Retransplantation was performed in three cases in Group control
(due to arterial thrombosis n = 2 and primary non-function n = 1)
and none in Group Precond (P = 0.2). One patient from Group control
who was on the waiting list for elective retransplantation for
ischaemic cholangitis dropped out because of recurrent cancer.
Long-term survival
The mean follow-up period was 20.6  14.4 months. Four
patients in Group control and none in Group Precond (P = 0.1) died.
These four deaths occurred 3, 14, 21 and 24 months after trans-
plantation and were as a result of cancer recurrence (3 cases) and
intracerebral haemorrhage (1 case). No difference in 1-year
survival was found between the groups (86.1% and 95.5% for
Group control and Group Precond, respectively, P = 0.08, logrank).
Actuarial graft survival rate was 88.9% and 80.2% at 1 year for
Group control and Group Precond, respectively (P = 0.6).
Discussion
This single centre prospective study involving 44 consecutive cases
of elective adult-to-adult living related right lobe liver transplan-
tation is one of the few studies37,38 to evaluate the potential benefit
of ischaemic preconditioning of the graft in this model.
Ischaemic preconditioning had no effect on graft tolerance to
ischaemia–reperfusion injury, as shown by the similar peak AST
concentrations in the two groups (Fig. 1, Table 2).
Two human studies have evaluated the preconditioning-like
effect of reversible cardiac arrest in the cadaveric liver donor on
the post-transplantation outcome.26,27 Totsuka et al.26 showed that
livers from human donors who were resuscitated after cardiopul-
monary arrest had similar survival and function to those from
other donors. In addition, these authors showed that the post-
transplantation serum concentrations of transaminases were
lower in patients who received organs from donors with prior
cardiopulmonary arrest compared with those without. Con-
versely, Wilson et al.27 reported that reversible cardiac arrest prior
to graft procurement did not trigger any preconditioning benefit
in liver transplantation. These two studies, together with the large
body of experimental evidence showing that ischaemic precondi-
tioning protects against cold ischaemia–reperfusion injury, were
the impetus for our study. The discrepancy between our disap-
pointing results and previous results in favour of ischaemic
preconditioning may be as a result of several factors. First, the
occurrence of ischaemic preconditioning differs between different
tissues within a given species and within the same tissue in differ-
ent species.8,39–47 Second, the many mechanisms beyond the scope
of our study of ischaemic preconditioning9,10,48 might be involved
differently in different models. Third, biases in our study might
mask any effect of ischaemic preconditioning. These biases
include small graft size, the preconditioning protocol and the
choice of study design. One of the biases could be the short cold
ischaemia time (below 3 h in all our cases; median = 82 min). This
potential bias, which remains to be proven, is however counter-
balanced by the absence of an effect of preconditioning on
ischaemia reperfusion subsequent to the warm ischaemia between
portal and arterial revascularization (always >30 min, the cut-off
value of clinical studies evaluating the value of IPC in warm
ischemia during liver resection).18,19 Pharmacological precondi-
tioning protocols that do not include a warm ischaemia step (with
portal triad clamping) might prevent this negative effect.49–51
Ischaemic preconditioning did not improve graft function, as
shown by the similar prothrombin time and bilirubin concentra-
tion in the two groups at all time points of the study (Fig. 2). This
is in accordance with the results of the two human studies
that evaluated the preconditioning-like effect of reversible
cardiac arrest in the cadaveric donor.26,27 In these studies, post-
transplantation prothrombin times and bilirubin concentrations
were similar regardless of whether the donor had sustained
temporary cardiac arrest prior to procurement or not. None of
the animal studies on ischaemic preconditioning in cold
ischaemia measured the coagulation factors and bilirubin levels
after ischaemic preconditioning of the liver. However, Adam
et al.52 showed that preconditioning of the liver graft was associ-
ated with altered liver function compared with a control group
in a rat model. In a randomized study, we showed that 10 min
of ischaemic preconditioning of the whole liver in the cadaveric
donor improved graft tolerance to ischaemia–reperfusion.
However, this protective effect tended to alter graft function.53
Conversely, Koneru et al.54 showed in a randomized study that
5 min of ischaemic preconditioning of the whole liver in the
deceased donor did not trigger any benefit in the recipient in
terms of ischaemia–reperfusion injury and graft function.
The preconditioning protocol had neither a positive nor a nega-
tive effect on the outcome of liver transplantation. The clamping
of the graft pedicule was not associated with an increased risk
of portal or arterial thrombosis in the recipient. Interestingly,
when comparing the two groups, only patients in the Group control
appeared to require retransplantation. Besides the fact that this
difference was statistically non-significant and purely attributable
to technical problems (2 patients) or graft primary non-function
(1 patient), we could not confidently confirm that the clamping
of the graft pedicule is not associated with an increased risk of
portal or arterial thrombosis in the recipient as our study was
underpowered to demonstrate a difference in this criterion.
Likewise, ischaemic preconditioning of the graft had no effect
on donor outcome. Ischaemic preconditioning had no effect on
the post-operative concentration of transaminases or on liver
function tests i.e. prothombin time and bilirubin concentration.
However, it is worth noting that the absence in our study of any
effect of ischaemic preconditioning of the graft can also be inter-
preted as results of an intervention which is already compensated
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by advantages such as shorter transection time in LDLT donors,
or healthy donors who have no underlying liver disease such as
steatosis.
In addition, the results of this study differ from those reported
by Arai et al. in a rat model.23 In the study by Arai et al.
ischaemic preconditioning of one half of an individual rat liver
decreased non-parenchymal cell killing, used as an index of
sinusoidal endothelial cell killing, not only on the precondi-
tioned side but also on the contralateral side. This potential
effect, termed heterologous preconditioning, which has also been
observed in the heart model,55 was not confirmed in the donors
of our study.
Lastly, we also found that ischaemic preconditioning not only
did not have any clinical impact on the recipients’ outcome, but
also that ischaemia–reperfusion injury was similar in the post-
reperfusion biopsies of the patients belonging to the control and
preconditioning group. However, our study did not provide any
clinical information about the changes at a molecular level (such
as over expression of IL1-Ra, Bcl-2 and NO), thought to be
responsible for neutralizing the pro-inflammatory responses of
interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-a) to
ischaemia reperfusion.56 Concerning the later changes (molecu-
lar) induced by ischaemia–reperfusion injury, we feel that newer
prospective randomized studies in the same settings should be
conducted to better evaluate their effects.
Conclusion
Ischaemic preconditioning of right hepatic lobe liver grafts
in living donors does not seem to protect against ischaemia–
reperfusion injury in the recipient. Ischaemic preconditioning of
the graft did not have deleterious effects on graft function, or on
morbidity or mortality rates. Ten minutes of ischaemic precon-
ditioning had no consequence on the post-operative outcome of
the donors. As donor safety and immediate and sufficient graft
function are the primary goals of LRLT, the use of ischaemic
preconditioning (ten minutes of warm ischemia) is not appropri-
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